The mental-health-focused biopharma Atai Life Sciences N.V. (Nasdaq:ATAI) has named Stephen Bardin to be its chief financial officer (CFO) in the third quarter of 2022.
“Atai’s mission to transform mental health is deeply personal and meaningful for me — as it is for so many,” Bardin shared in a LinkedIn post.
Most recently, Bardin was the senior vice president of finance and operations at BridgeBio Pharma, Inc. (Nasdaq:BBIO).
Bardin will begin her tenure at Berlin-based Atai as deputy CFO and CFO designate on June 27 and will assist CFO Greg Weaver in transitioning to an advisory role, which is expected to conclude on March 31, 2023.
At BridgeBio, Bardin was instrumental in raising more than $2 billion in various financial transactions.
Bardin has also held senior finance and operational roles at Myovant Sciences, Halo Neuroscience, Inc. and the Boston Consulting Group.
Bardin earned an MBA from the Stanford …